While much progress in precision therapy has been made in SCN1A mutations, primarily associated with Dravet syndrome, this section focuses on precision therapies targeting monogenic channelopathies more commonly linked to LGS, including SCN2A and SCN8A (sodium channels), KCNQ2, KCNA2, and KCNT1 (potassium channels), and CACNA1A (calcium channels) [19,20]. This evidence concerns the gene SCN2A and Lennox-Gastaut syndrome.